• Innate Pharma investor deck centered on three lead oncology programs, with lacutamab in cutaneous T-cell lymphoma, IPH4502 in solid tumors, monalizumab in non-small cell lung cancer.
• Lacutamab Phase 2 TELLOMAK in Sézary syndrome post-mogamulizumab reported global ORR 42.9% with median duration of response 25.6 months; median PFS 8.3 months.
• Company outlined plan to start TELLOMAK-3 Phase 3 in H2 2026, positioning it as confirmatory trial in Sézary syndrome versus romidepsin with primary endpoint PFS by blinded independent central review; potential accelerated approval in 2027 shown on regulatory timeline.
• IPH4502 Phase 1 program cited preliminary anti-tumor activity in heavily pre-treated advanced solid tumors, including urothelial cancer post-enfortumab vedotin, with favorable safety profile to date.
• Monalizumab PACIFIC-9 Phase 3 in unresectable NSCLC has completed enrollment, with Phase 3 readout targeted for H2 2026; deck reiterated up to USD 825 million potential milestones, 50% EU profit share, double-digit royalties in US and rest of world.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.